XTL Biopharmaceuticals Ltd (XTLB) stock

XTLBNasdaqPharmaceutical Preparations

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026Score 0/30

$1.64−0.02 (-1.20%)

Close on Nov 12, 2026Market cap $15.52MP/E –Yield –

XTL Biopharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2017 it was -$1.25M.

Period	Period end	Value	Change
FY2017	Dec 31, 2017	-$1.25M	–
FY2016	Dec 31, 2016	-$2.56M	–
FY2015	Dec 31, 2015	-$3.60M	–

See a number that looks wrong?